| Date | Time | Source | Headline | Symbol | Company |
| 08/03/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023 | NASDAQ:DARE | Dare Bioscience Inc |
| 07/31/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth | NASDAQ:DARE | Dare Bioscience Inc |
| 07/21/2023 | 4:01PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:DARE | Dare Bioscience Inc |
| 07/11/2023 | 5:30PM | GlobeNewswire Inc. | Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems | NASDAQ:DARE | Dare Bioscience Inc |
| 07/11/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women | NASDAQ:DARE | Dare Bioscience Inc |
| 07/06/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder | NASDAQ:DARE | Dare Bioscience Inc |
| 07/05/2023 | 8:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:DARE | Dare Bioscience Inc |
| 07/05/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis | NASDAQ:DARE | Dare Bioscience Inc |
| 06/22/2023 | 8:00AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DARE | Dare Bioscience Inc |
| 06/21/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women | NASDAQ:DARE | Dare Bioscience Inc |
| 06/14/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference | NASDAQ:DARE | Dare Bioscience Inc |
| 06/09/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society | NASDAQ:DARE | Dare Bioscience Inc |
| 06/05/2023 | 8:06AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DARE | Dare Bioscience Inc |
| 06/05/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder | NASDAQ:DARE | Dare Bioscience Inc |
| 06/01/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference | NASDAQ:DARE | Dare Bioscience Inc |
| 05/31/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine | NASDAQ:DARE | Dare Bioscience Inc |
| 05/11/2023 | 4:04PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:DARE | Dare Bioscience Inc |
| 05/11/2023 | 8:11AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DARE | Dare Bioscience Inc |
| 05/11/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update | NASDAQ:DARE | Dare Bioscience Inc |
| 05/04/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023 | NASDAQ:DARE | Dare Bioscience Inc |
| 04/27/2023 | 4:10PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:DARE | Dare Bioscience Inc |
| 04/27/2023 | 4:09PM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:DARE | Dare Bioscience Inc |
| 04/20/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6% | NASDAQ:DARE | Dare Bioscience Inc |
| 04/19/2023 | 8:00AM | GlobeNewswire Inc. | David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany | NASDAQ:DARE | Dare Bioscience Inc |
| 04/18/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy | NASDAQ:DARE | Dare Bioscience Inc |
| 04/17/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference | NASDAQ:DARE | Dare Bioscience Inc |
| 03/30/2023 | 8:06AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DARE | Dare Bioscience Inc |
| 03/30/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update | NASDAQ:DARE | Dare Bioscience Inc |
| 03/23/2023 | 8:00AM | GlobeNewswire Inc. | Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023 | NASDAQ:DARE | Dare Bioscience Inc |
| 03/13/2023 | 8:22AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DARE | Dare Bioscience Inc |